Polycystic ovary syndrome (PCOS) is a multifaceted condition characterized by chronic anovulation and excess ovarian activity, in contrast to other causes of anovulation that involve ovarian dormancy or primary insufficiency. Recent studies indicated that PCOS is associated with low-grade chronic inflammation and that women with PCOS are at increased risk of non-alcoholic fatty liver disease. The inflammatory and metabolic derangements associated with PCOS are explained in part by the coexistence of insulin resistance and obesity but are further fueled by the androgen excess. New insights into the regulation of hormones and cytokines in muscle and fat tissue support the concept that PCOS is a systemic syndrome. The therapeutic plan should be tailored to the patient phenotype, complaints, and reproductive desire. Of note, the aromatase inhibitor letrozole seems to be more effective than the reference drug clomiphene citrate to treat infertility due to PCOS. Integral management by a multidisciplinary team may help the patients to adhere to lifestyle interventions and thereby reduce body adiposity and recover their metabolic and reproductive health.
Good quality thin films of poly(2,5-bis(2′-ethyl-hexyl)–1,4-phenylenevinylene) (BEH–PPV) were optically characterized by photoluminescence, absorption, and Raman scattering techniques. The temperature evolution of the vibronic structures in the photoluminescence and absorption spectra was analyzed. At low temperatures it was possible to identify the different phonon modes that contribute to the vibronic spectra. The correlation of the Raman and photoluminescence spectra enabled us to conclude that the main vibrational modes are the two most intense Raman bands at 1310 and 1579 cm−1. The emission efficiency highly increases and the absorption spectra become much more resolved with decreasing temperature. The temperature dependence of the zero-phonon line in the absorption and photoluminescence measurements is attributed to an increase of the effective conjugation length at low temperatures. The results from the polarization-resolved photoluminescence demonstrated the high degree of the in-plane structural order in the BEH–PPV films, corroborating to the relatively high conjugation length obtained from the analysis of the Huang–Rhys factor.
A correlation between thermal, optical and morphological properties of self-sustained films formed from blends of poly(3-hexylthiophene) (P3HT) and thermoplastic polyurethane (TPU), with 1, 10 and 20 wt% of P3HT in TPU, is established. Images of scanning electron microscopy (SEM) show the formation of domains of P3HT into the TPU matrix, characterizing the blend material as heterogeneous. The heat capacity (C(p)) dependence on P3HT contents was investigated in a large temperature interval. In the region of the TPU glass transition, the difference between the experimental and predicted ΔC(p) values is more pronounced for the 1 wt% case, which strongly suggests that in this case there is a higher influence of the P3HT chains on the TPU matrix. The SEM images for the 1 wt% blended film present the formation of the smallest P3HT domains in the TPU matrix. The relatively high reduction of the PL intensity of the pure electronic transition peak in the 1 wt% blended film, in comparison to the other blended films and also to a pure P3HT film, favours the assumption that the smallest P3HT domains are at the origin of a more structural disordered character. This fact is in agreement with the results obtained by Raman spectroscopy and also by photoluminescence resolved by polarization in stretched self-sustained films, showing an ample correlation between morphological, thermal and optical properties of these blended materials. In addition, the thermoplastic properties of the polyurethane configure very good conditions for tensile drawing of P3HT and other conjugated polymer molecules.
All patients with heart diseases should undergo risk stratification to predict those who are at high risk for short- and long-term adverse outcomes. Carbohydrate antigen 125 (CA125) is a glycoprotein produced by mesothelium that has clinical role in ovarian cancer monitoring. However, as it is not specific for ovarian cells, CA125 could also be used in heart diseases to monitor congestion and inflammation. Pericarditis, atrial fibrillation, heart failure and coronary artery disease are some scenarios in which this biomarker was studied.CA125 identifies patients at high risk of rehospitalizations and death, in addition to being associated with hemodynamic data (ejection fraction and right atrial pressure). Hence, CA125 is a tool for risk stratification in heart diseases.
Polycystic Ovary Syndrome (PCOS) is the most common cause of subfertility associated to metabolic disorders. The aim of this study was to correlate metabolic and proinflammatory factors in women with PCOS. The frequency of Plasminogen Activator Inhibitor-1 (PAI-1) promoter 4 G/5 G polymorphism was also compared to healthy controls. We evaluated 79 PCOS and 79 healthy women. PAI-1 levels are positively correlated with proinflammatory factors in PCOS group. 4 G allele in PAI-1 gene was more frequent in PCOS and the 4G/4 G genotype was associated with increased PAI-1 levels. A correlation between insulin resistance and proinflammatory and overweight was also observed. C-reactive protein, serum levels of vascular cell adhesion molecule-1 (sVCAM-1), Lipid Accumulation Product (LAP) and vitamin D are good tools to evaluated factors associated to cardiovascular risk in women with PCOS.
Carbohydrate antigen 125 (CA125) is a congestion and inflammation biomarker and has been proved to be related to a worse prognosis in heart diseases. However, the precise relationship between elevated CA125 in patients with ST-segment elevation myocardial infarction (STEMI) has not yet been sufficiently studied. We set out to determine the association of CA125 with all-cause mortality at 6 months in STEMI. CA125, N-terminal pro brain natriuretic peptide (NTproBNP) and high sensitive C-reactive protein (hs-CRP) were measured in 245 patients admitted consecutively with STEMI undergoing coronary angioplasty. The mean age in our sample was 63.7 years, 64.9% were males, 28.3% had diabetes and 17.7% presented with acute heart failure (Killip ≥ 2). The median serum level of CA125 was 8.1 U/ml. At 6 months, the rate of all-cause mortality was 18% (44 patients). Receiver operating characteristic curve analysis demonstrated that CA125 presented similar performance to predict mortality as NTproBNP and hs-CRP. Patients with CA125 ≥ 11.48 had a higher rate of mortality (Hazard Ratio = 2.07, 95% confidence interval = 1.13-3.77, p = 0.017) than patients with CA125 < 11.48. This study suggests that elevated CA125 levels might be used to identify patients with STEMI with a higher risk of death at 6 months. CA125 seems to be a similar predictor of mortality compared to NTproBNP and hs-CRP. Myocardial infarction with ST-segment elevation (STEMI) is a life-threatening disorder with high morbidity and mortality despite advances in treatment. Patients presenting with STEMI tend to be heterogeneous and immediate risk stratification at the time of presentation is essential for optimal management 1-4. Markers of congestion and inflammation, such as natriuretic peptides (NP) and high sensitive C-reactive protein (hs-CRP), have been shown to be prognostic markers. However, the biomarkers currently available are not perfect, and their correct interpretation requires careful consideration of the specific clinical scenario 5. Carbohydrate antigen 125 (CA125) is a congestion and inflammation biomarker. It has been studied in patients with heart diseases, especially heart failure 6. However, the precise relationship between elevated CA125 in patients with STEMI and cardiovascular events has not yet been sufficiently studied. This study set out to evaluate the relationship between CA125 and mortality in STEMI patients in comparison with N-Terminal pro brain natriuretic peptide (NTproBNP) and hs-CRP. Methods patients and study design. This was a prospective cohort at a single center. Patients consecutively admitted with STEMI undergoing primary angioplasty were included. The diagnosis of STEMI was made based on the third universal definition 7. Two hundred and seventy one patients were considered to be included. Patients were excluded if they had chronic heart failure (n = 3), previous coronary revascularization (n = 11), kidney failure (n = 8), absence of severe coronary disease (n = 4), end-stage liver disease, ongoing infection or malignancy.
BackgroundSmall vessels represent a risk factor for restenosis in percutaneous coronary angioplasty (PCA). The Sparrow® self-expanding drug-eluting stent, which has a lower profile than the current systems, has never been tested in this scenario. ObjectivesTo evaluate the late effectiveness of the Sparrow® drug-eluting stent, regarding in-stent late lumen loss (LLL). MethodsPatients with ischemia, symptomatic or documented, were submitted to PCA in vessels with reference diameter < 2.75 mm, divided into two groups regarding Sparrow® stent type: group 1: Sparrow® drug-eluting stent (DES), group 2: Sparrow® bare metal stent (BMS). Clinical follow-up duration was 12 months. Evaluation using quantitative coronary angiography (QCA) was performed immediately and at 8 months. A decrease of over 65% of in-stent LLL with DES was estimated to calculate sample size. IBM® SPSS software, release 19 (Chicago, Illinois, USA) was used for the statistical analysis. ResultsA total of 24 patients were randomized, 12 in each group. The DES and BMS groups were similar in age (63.25 ± 10.01 vs. 64.58 ± 11.54, p = 0.765), male gender (58.3% vs. 33.3%, p = 0.412), risk factors and all angiographs aspects. Immediate results were satisfactory in both groups. At 8 months in-stent late lumen loss was significantly lower in DES than in BMS group (DES vs. BMS 0.25 ± 0.16 0.97 ± 0.76, p = 0.008). ConclusionIn small-vessel PCA, the Sparrow® DES determined significant reduction in in-stent LLL, when compared to Sparrow® BMS.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
334 Leonard St
Brooklyn, NY 11211
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.